Log in
The University of Manchester
PhD- Biochemistry- Immunology; BSc- Biochemistry- Immunology- The University of Manchester
Pharmaceutical Industry; Mergers & Acquisitions; Drug Discovery; Start-ups; Clinical Trials;Biotechnology; Bio-pharmaceuticals; Life-sciences; Clinical Development; Drug Development; Pharmacology; Medical Devices; Vaccines
Roger Aston is Director and Chairman of Oncosil Ltd and one of the most experienced and commercially astute people in drug commercialisation in Australia. Roger brings more than 20 years of experience witinin the pharmaceutical and health care industries in senior roles of the United Kingdom, Asia-Pacific, and Australia. He is Director and Chairman of five public stock exchange listed companies in Australia and on the Board of two private UK companies; he is currently a director and Executive Chairman of PharmAust Ltd, Chairman of Immuron Ltd, and Chairman of Oncosil Medical Ltd. Roger earned his PhD in Biochemistry- Immunology and a BSc in Biochemistry- Immunology from the University of Manchester. In his free time, he enjoys reading, spending time with family, and mentoring emerging professionals. Roger started his career at major pharmaceutical company, Wellcome (now Glaxo Smith Kline) and has also worked for QinetiQ Ltd. Roger also served on the federal government's IRD board sub-committee for biologicals. He has been CEO of many successfull companies, i.e. Mayne Pharma Group Ltd. Roger has held executive, non-executive director or chairman positions on a number of boards including Peptech (Arana), Cambridge Antibody Technology, Clinuvel, Halcygen, Cambridge Drug Discovery, and pSivida. During his career, Roger Aston has been closely involved in start-up companies and major pharmaceutical companies. He has had a hands-on role in company restructuring, improving effectiveness and productivity in both small and significant businesses.
